1Hogg J C. A brief review of chronic obstructive pulmonary disease [J].Can Respir J, 2012,19(6):381-384. 被引量：1
2Calverley P M, Anderson J A, Celli B, et al. Salmeterol and fiutica- sone propionate and survival in chronic obstructive pulmonary disease[J].N Engl J Med,2007,356(8):775-789. 被引量：1
5Hoshino M, Ohtawa J. Effects of adding salmeterol/fluticasone propionate to tiotropium on airway dimensions in patients with chronic obstructive pulmonary disease[J]. Respirology, 2011, 16 (1):95-101,. 被引量：1
7Pasqua F, Biscione G, Crigna G, et al. Combining triple therapy and pulmonary rehabilitation in patients with advanced COPD: a pilot study[J]. Respir Med, 2010, 104(3):412-417. 被引量：1
8Tashkin D P, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease[J].N Engl J Med,2008,359 (15):1543-1554. 被引量：1
5GOLD Executive Committee [DB/OL]. Global Strategy for Diagnosis, Management, and Prevention of COPD, November 2006 [ 2006-11-18 ]. http://www. Goldcopd. com/ Guidelineitem. asp? 11= 2 & 12 = 1 &intld = 989. 被引量：1
6Jones PW. Testing health status (" quality of life ") questionnaires for asthma and COPD. Eur Respir J, 1998,11 : 5- 6. 被引量：1
7Celli BR,MacNee W, ATS/ERS Task Force. Standard for the diagnosis and treatment of patients with COPD:a summary of the AST/ERS position paper. Eur Respir J, 2004,23 : 932-946. 被引量：1
8Goldkorn A, Diotto P, Burgess C, et al. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol. Respirology, 2004,9 : 102-108. 被引量：1
9Sin DD, Wu L, Anderson JA, et al. Inhaled eorticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 2005,60:992-997. 被引量：1
10Szafranski W,Culier A,Ramirez A,et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J, 2003,21:74-81. 被引量：1
4Frith PA, Thompson PJ, Ratnavadivel R,et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial f-J]. Thorax,2015,70(6) :519-527. 被引量：1
5Liu Y, Shi H, Sun X,et al. Benefits of adding flutieasone propi- onate/salmeterol to tiotropium in COPD: a meta~analysis I-J-1. Eur J Intern Med,2014,25(5):491-495. 被引量：1
6Ismaila A, Corriveau D, Vaillancourt J,et al. Impact of adher- ence to treatment with tiotropium and fluticasone propionate/ salmeterol in chronic obstructive pulmonary diseases patients EJ]. Curr Med Res Opin,2014,30(7) :1427-1436. 被引量：1
7Maltais F, Mahler DA, Pepin V,et al. Effect of fluticasone pro- pionate/salmeterol plus tiotropium versus tiotropium on walking endurance in COPD [J']. Eur Respir J, 2013,42 (2) ~ 5a9-541. 被引量：1
8Hoshino M, Ohtawa J. Effects of tiotropium and salmeterol/flu- tieasone propionate on airway wall thickness in chronic obstruc- tive pulmonary disease [J]. Respiration, 2013,86 (4) : 280-287. 被引量：1
9Szmidt M. The influence of treatment with formoterol, formot- erol with tiotropium, formoterol with inhaled glucocorticosteroid and tiotropium on lung functions, tolerance of exercise and sim- ple, morning everyday activities in patients with chronic ob- structive pulmonary disease (COPD)[J]. Pneumonol Alergol Pol,2012,80(3) :255-262. 被引量：1
10Keating GM. Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary dis- ease I-J]. Drugs,2012,72(2) :273-300. 被引量：1
